How Insilico Medicine’s Virtual Aging Cell could bring biological time into AI drug discovery
Insilico Medicine is building an age-aware Virtual Aging Cell for drug discovery, but experimental validation will determine its real scientific value.
Pharma & Biotech
Pharma & Biotech
A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates
Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.
Pharma & Biotech
Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery
Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.